Piper Sandler raised the firm’s price target on Quest Diagnostics (DGX) to $165 from $150 following quarterly results. The firm remains on the sidelines with a Neutral rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $175 from $163 at Argus
- Quest Diagnostics price target raised to $174 from $160 at Mizuho
- Snap upgraded, McDonald’s downgraded: Wall Street’s top analyst calls
- Quest Diagnostics awarded several contracts by CDC
- Quest Diagnostics price target raised to $185 from $165 at Citi